Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Demicheli, Romano ^a   Ardoino, Ilaria ^a   Boracchi, Patrizia ^b   Coradini, Danila ^b   Agresti, Roberto ^a   Ferraris, Cristina ^a   Gennaro, Massimiliano ^a   Hrushesky, William J M ^c   Biganzoli, Elia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PROGNOSIS; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CHEMISTRY; ITALY; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEGMENTAL MASTECTOMY; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; ITALY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 78649453758     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-656     Document Type: Article

References (35)

1. Demicheli R, Ardoino I, Biganzoli E, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G. Recurrence and mortality for breast cancer patients undergoing mastectomy according to Estrogen Receptor status: different mortality pattern but comparable recurrence dynamics. Cancer Sci 2010, 101:826-830. 10.1111/j.1349-7006.2009.01472.x, 20132222.
2. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998, 52:227-237. 10.1023/A:1006133418245, 10066085.
3. Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009, 116:595-602. 10.1007/s10549-008-0200-5, 2711214, 18830816.
4. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 2008, 10:R83. 10.1186/bcr2152, 2614518, 18844974.
5. Hess KR, Pustzai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-118. 10.1023/A:1022166517963, 12611463.
6. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000, 59:271-278. 10.1023/A:1006308619659, 10832597.
7. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984, 1:588-5891. 10.1016/S0140-6736(84)90995-4, 6142305.
8. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998, 351:1451-1467. 10.1016/S0140-6736(97)11423-4, 9605801, Early Breast Cancer Trialists' Collaborative Group.
9. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst 2006, 98:948-951. 10.1093/jnci/djj295, 16849671.
10. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127. 10.1186/1471-2164-7-127, 1489944, 16729877.
11. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-5984.
12. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981, 305:6-11. 10.1056/NEJM198107023050102, 7015141.
13. Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 1990, 26:671-673. 10.1016/0277-5379(90)90114-9, 2144153.
14. Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, Rilke F, Sacchini V, Saccozzi R, Savio T. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993, 328:1587-1591. 10.1056/NEJM199306033282202, 8387637.
15. Marubini E, Mariani L, Salvadori B, Veronesi U, Saccozzi R, Merson M, Zucali R, Rilke F. Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet 1996, 347:1000-1003. 10.1016/S0140-6736(96)90145-2, 8606561.
16. Demicheli R, Retsky MW, Hrushesky WJM, Baum M. Tumor dormancy and surgery-driven dormancy interruption in breast cancer: learning from failures. Nature Clin Pract Oncol 2007, 4:699-710.
17. Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF. "Residual" mammary carcinoma following simulated partial mastectomy. Cancer 1975, 35:739-747. 10.1002/1097-0142(197503)35:3<739::AID-CNCR2820350329>3.0.CO;2-5, 163139.
18. Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer 1996, 74:820-824. 2074702, 8795588.
19. Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W, Wang JP. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?. J Steroid Biochem Mol Biol 1997, 61:267-271. 10.1016/S0960-0760(97)80022-2, 9365200.
20. Haveman J, Rodermond H, vanBree C, Wondergem J, Franken NAP. Residual late radiation damage in mouse stromal tissue assessed by tumor bed effect. J Radiat Res 2007, 48:107-112. 10.1269/jrr.0631, 17299252.
21. Shao C, Folkard M, Held KD, Prise KM. Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer 2008, 8:184. 10.1186/1471-2407-8-184, 2443807, 18590532.
22. Gupta GP, Massaguè G. Cancer metastasis: building a framework. Cell 2006, 127:679-695. 10.1016/j.cell.2006.11.001, 17110329.
23. Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1889, 1:571-573.
24. Hodges GM, Hicks RM, Spacey GD. Epithelial-stromal interactions in normal and chemical-carcinogen treated adult bladder. Cancer Res 1977, 37:3720-3730.
25. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000, 60:1254-1260.
26. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004, 117:1495-502. 10.1242/jcs.01000, 14996910.
27. Decosse JJ, Glossens CL, Kluzma JF, Unsworth D. Breast cancer: induction of differentiation by embryonic tissue. Science 1973, 181:1057-1058. 10.1126/science.181.4104.1057, 4269415.
28. Fukamachi HA, Mizuno T, Kim JS. Gland formation of human colon cancer cells combined with foetal rat mesenchyme in organ culture: an ultrasctuctural study. J Cell Sci 1987, 87:615-621.
29. Dotto GP, Weinberg RA, Ariza A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci USA 1988, 85:6389-6393. 10.1073/pnas.85.17.6389, 281977, 2457913.
30. Hayashi N, Cunha GR. Mesenchyme-induced changes in neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res 1991, 51:4924-4930.
31. Kuperwasser C. Reconstruction of functionally normal and malignant breast tissues in mice. Proc Natl Acad Sci USA 2004, 101:4966-4971. 10.1073/pnas.0401064101, 387357, 15051869.
32. Brinster RL. The effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med 1974, 140:1049-1056. 10.1084/jem.140.4.1049, 2139639, 4610074.
33. Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975, 72:3585-3589. 10.1073/pnas.72.9.3585, 433040, 1059147.
34. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait R. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res 2001, 61:1320-1326.
35. Fisher B. Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980, 40:3863-74.